MedTrace Logo

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2023-04-03

No results posted yet for this study

Summary

The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.

Conditions

Interventions

DRUG

RVX000222

RVX000222 twice a day for 12 weeks

DRUG

Placebo

Placebo twice a day for 12 weeks

Sponsors & Collaborators

  • Resverlogix Corp

    lead INDUSTRY

Principal Investigators

  • Steve Nicholls, MD, PhD · Intravascular Ultrasound Core Lab, Clevelend Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-06-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01058018 on ClinicalTrials.gov